查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1840882

miRNA定序與檢測市場：依產品類型、技術、應用、最終使用者、工作流程與樣本類型分類－全球預測，2025-2032年

miRNA Sequencing & Assay Market by Product Type, Technology, Application, End User, Workflow, Sample Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，miRNA 定序和檢測市場將成長至 11.2765 億美元，複合年成長率為 14.55%。

關鍵市場統計數據
基準年 2024 3.8021億美元
預計年份：2025年 4.3569億美元
預測年份 2032 11.2765億美元
複合年成長率 (%) 14.55%

全面介紹最新的miRNA定序和檢測技術，重點闡述其科學潛力以及臨床應用轉化的挑戰。

微型RNA定序和檢測技術已迅速從一項小眾研究發展成為轉化研究和臨床開發中分子譜分析策略的核心要素。樣本處理、文庫建構化學和分析流程的進步提高了小RNA檢測的可靠性，而儀器設備的改進則縮短了檢測週期，降低了常規應用門檻。因此，包括學術機構、受託研究機構、醫院、診斷實驗室、製藥公司和生物技術公司在內的相關人員，不僅將微小RNA解決方案視為探索性工具，而且將其視為生物標記開發、伴隨診斷和標靶治療發現的候選方案。

儘管取得了這些進展，但該領域仍面臨持續的技術挑戰，這些挑戰決定著技術的應用決策。低起始量、家族成員間的序列相似性以及異構體miRNA的存在，都要求設計高度選擇性的檢測方法並進行嚴格的品管。此外，將原始定序資料轉化為可操作特徵的生物資訊工作流程仍然是關鍵的區分因素，而可重複的比對、標準化和註釋策略則決定了候選miRNA能否實現轉化應用。監管和臨床檢驗途徑進一步增加了複雜性，凸顯了整合檢測方法的重要性，這些方法需要將可靠的濕實驗方案與檢驗的計算流程相結合。

從探索性科學到臨床效用，需要對檢測標準化、實驗室間重複性研究以及連接儀器供應商、套件製造商和服務供應商的夥伴關係進行協同投資。在此背景下，可互通的工作流程和與供應商無關的數據格式至關重要，使研究人員和臨床醫生能夠跨平台比較結果，並加速將miRNA訊號轉化為診斷和治療見解。綜上所述，當miRNA定序和檢測技術以嚴謹的方法論和與臨床目標的策略一致性實施時，它們將成為精準醫療舉措的關鍵推動因素。

一項關鍵的變革性轉變旨在重塑miRNA測序和檢測工作流程，從而實現可擴展的臨床轉化路徑和整合服務模式。

miRNA定序和檢測方法的發展正經歷著數次變革性的轉變，這些轉變正在重新定義技術預期和商業策略。次世代定序平台提高了靈敏度和多重分析能力，能夠從少量樣本同時分析數百種小RNA。同時，檢測化學和文庫製備技術的改進降低了偏差，提高了定序批次間的一致性，使得不同研究之間的可比性日益增強，並激發了臨床研究項目的濃厚興趣。

同時，RT-qPCR、微陣列和定序技術的融合建構了一個分層診斷生態系統，其中高通量定序發現與使用qRT-PCR檢測和微陣列晶片進行標靶驗證相輔相成。這種多模態途徑支持嚴格的生物標記合格：發現、正交驗證以及在受監管的臨床檢測環境中的應用。與濕實驗室的發展同步，生物資訊學和機器學習演算法也日趨成熟，能夠應對小RNA特有的挑戰，例如異構體miRNA的檢測、序列修剪偽影和跨平台標準化，從而提高最終特徵的可靠性。

營運方面的變化也顯而易見。服務供應商正在擴展其端到端解決方案的服務範圍，將樣本物流、定序執行和結果解讀相結合；而儀器和試劑製造商則優先考慮能夠提高臨床實驗室易用性的整合工作流程。政策制定者和支付方的討論日益聚焦於分子生物標記的證據標準，這促使檢測方法開發人員、臨床實驗室和監管機構之間加強合作，以建立驗證模板和性能基準。總而言之，這些轉變表明，miRNA檢測正從實驗性工作流程轉向精準醫療流程中的標準化組成部分。

重組 miRNA定序和檢測業務的供應鏈策略、採購慣例和韌性計劃

近期貿易政策的調整，為依賴進口設備、耗材和試劑的企業採購計畫、供應鏈設計和成本管理帶來了更多複雜性。影響進口檢測設備和試劑的關稅措施大幅增加了許多市場參與企業的到岸成本，促使採購團隊重新評估供應商關係、合約條款和庫存策略。為此，一些企業正加快步伐，透過供應商多角化和從地理位置較近的製造商採購關鍵投入品，來減輕跨境政策變化的影響。

這些動態對營運產生了重大影響。科學研究和臨床實驗室正在調整採購計劃，增加關鍵試劑的儲備，並擴大供應商資格資格確認範圍，納入更多國內和區域合作夥伴。製造商和經銷商正在探索本地組裝、替代物流路線以及重新調整定價模式，以在應對利潤壓力的同時維持客戶供應。營運國際定序中心的服務供應商也在評估生產能力的選址，以及如何調整客戶定價以反映新增關稅和合規成本。

持續的關稅壓力往往會促使企業投資區域製造能力和建立策略夥伴關係關係，從而降低對單一供應基地的依賴。同時，採購人員和研發負責人必須權衡供應彈性與替代零件的技術性能之間的利弊。密切注意政策動態，並積極與供應商溝通，了解庫存情況、交貨前置作業時間和應急計畫，對於維持營運連續性以及按時完成miRNA檢測開發和臨床驗證至關重要。

綜合考慮產品類型、技術、應用、工作流程、最終用戶和樣品類型等因素進行市場細分，可為策略投資提供基礎。

解讀市場需要關注多個細分維度，這些維度共同決定了產品設計、應用路徑和使用者需求。根據產品類型，相關人員應評估表達譜檢測試劑套件的各種選擇，包括微陣列套件、qRT-PCR套件、定序試劑套件、定序平台以及涵蓋生物資訊學和定序服務的各種服務。微陣列和 qRT-PCR 試劑套件通常針對特定標靶和臨床通量進行最佳化，而定序試劑套件和平台則著重於發現廣度和多重定序能力。提供生物資訊學和定序執行服務則彌合了原始資料生成和可操作解讀之間的鴻溝。

技術部分重點介紹了微陣列、次世代定序和 RT-qPCR 方法的共存，每種方法在通量、靈敏度和每個樣本的成本方面都有不同的平衡：微陣列解決方案對於標準化面板和比較研究仍然很有價值，RT-qPCR 仍然是靶標檢驗和臨床檢測確認的主要手段，而次世代定序儀提供全面的發現和發現解析度的異構體。

臨床診斷、疾病研究和藥物研發對檢測效能、監管文件和長期可重複性都有獨特的要求。包括學術機構、受託研究機構)、醫院、診斷實驗室以及製藥和生物技術公司在內的最終用戶，各自需要不同的支持：學術團隊傾向於開放靈活的探索性研究通訊協定；CRO 重視檢測通量和標準化報告；臨床實驗室優先考慮檢驗的套件和合規性文件；而行業贊助商則重視與臨床試驗流程的整合。

透過對工作流程進行細分，所提供的服務分為耗材和服務兩部分。耗材包括套件、試劑和實驗室器皿，而服務包括數據分析和定序服務。耗材的品質和批次一致性對下游資料的可靠性有顯著影響。同時，提供進階分析的服務對於將複雜的小RNA產量、分解情況和基質效應。

提供可操作的區域洞察，描繪美洲、歐洲、中東和非洲以及亞太地區的創新中心、監管預期和商業現實。

區域動態對創新、臨床應用和商業性推廣的發生地點有著顯著影響，每個區域都存在獨特的監管、報銷和營運方面的考量，這些因素共同決定了應用的進程。美洲地區聚集了大量的學術研究中心、轉化研究所和臨床試驗活動，從而推動了對發現級測序平台和檢驗的臨床試驗檢測方法的需求。該地區的臨床實驗室通常需要在滿足監管機構的嚴格要求的同時，積極爭取大型醫院系統和專科診斷實驗室的早期應用，從而加速從生物標記發現到臨床評估的進程。

在歐洲、中東和非洲，監管協調工作和已建立的報銷框架正在創造一個環境，​​在這種環境下，檢測驗證和臨床級文件的重要性日益凸顯。在一些歐洲市場，公共研究資金和合作研究網路正在支持多中心驗證研究，從而提高交叉驗證和可重複性。在中東和非洲，對先進診斷和研究基礎設施的投資正在湧現，在這些市場中，物流的考量和供應鏈的韌性往往體現在籌資策略和夥伴關係關係中。

亞太地區兼具大規模生產能力、不斷成長的臨床研究能力以及對快速發展的分子診斷技術進行投資的醫院系統。本地製造地為試劑和耗材的供應提供了保障，而不斷壯大的臨床定序中心和受託研究機構則擴大了服務的覆蓋範圍。由於各地區的法律規範存在差異，導致臨床應用速度不一，但合作努力和官民合作關係往往能夠加速區域檢驗和商業化進程。了解這些區域差異有助於各組織根據各地區的營運實際情況和臨床優先事項，制定夥伴關係、在地化工作和打入市場策略。

深入洞察整合工作流程、策略夥伴關係和檢驗的服務模式如何為 miRNA 定序和檢測市場創造持久優勢

miRNA定序和檢測生態系統的競爭格局主要圍繞著透過整合的工作流程、檢驗證據和廣泛的服務來實現差異化。能夠提供從最佳化的文庫建構試劑套件到檢驗的生物資訊流程等端到端解決方案的儀器和試劑供應商，往往能夠降低臨床實驗室和轉化研究團隊的實施難度。同時，專業的生物資訊公司則透過提供可重複的小RNA分析流程和可擴展的解讀框架來創造價值。

策略夥伴關係和聯盟是拓展能力的常用途徑。套件生產商與臨床實驗室之間，或定序中心與製藥公司之間的共用，能夠實現聯合檢測方法開發和共享驗證研究，從而加速臨床合格。同時，臨床客戶和商業客戶之間的競爭凸顯了提供強大的客戶支援、培訓和文件的重要性，這些支援和文件應能證明檢測方法的性能和臨床效用。圍繞檢測化學和計算方法的智慧財產權既構成了准入壁壘，也為許可和白牌創造了機會。

卓越的營運能力將使市場領導脫穎而出。投資於品管系統、法規專業知識和透明檢驗數據的公司，往往能與醫院實驗室和診斷網路建立更牢固、更值得信賴的關係。此外，提供靈活商業模式的公司，例如訂閱式分析、樣本特異性定序服務和客製化檢測組合開發，將吸引更廣泛的終端用戶。最終，那些將嚴格的技術檢驗與符合臨床工作流程和不同醫療系統報銷實際情況的服務模式相結合的公司，將獲得永續的競爭優勢。

為產業領導者提供切實可行的優先建議，以加快 miRNA舉措。

為了最大限度地提高 miRNA 定序和檢測投資的回報，企業領導者應採取一系列策略行動，以提昇技術穩健性、供應鏈韌性和下游臨床整合能力。優先進行嚴格的檢測驗證和跨平台一致性研究，以證明其可重複性並推動臨床實驗室的應用。除了濕實驗驗證外，還應建立透明、版本控制的生物資訊流程和全面的文檔，以支援監管申報和臨床核准流程。

多元化籌資策略，降低突發關稅或物流中斷的風險，同時在可行的情況下，建立區域性生產或經銷夥伴。投資於供應商資質資格確認流程、擴大試劑庫存規劃，並制定能夠保障供應連續性的合約條款。從商業性角度來看，設計模組化產品，將探索性測序與正交驗證選項（例如 RT-qPCR 檢測和微陣列驗證）相結合，使客戶能夠在統一的框架內完成從研究到臨床驗證的整個流程。

我們透過培訓專案、共用方案以及現場或虛擬偵測設定服務來增強客戶能力，從而降低實驗室實施的風險。我們積極主動地儘早與臨床相關人員、支付方和監管顧問溝通，以明確證據產生路徑並降低報銷談判的風險。最後，我們優先考慮資料管治、互通性和安全性，以增強臨床醫生的信心並支援多中心檢驗工作。透過將技術嚴謹性與營運彈性以及以客戶為中心的服務設計相結合，各機構可以加速轉化醫學的進展，並將自身定位為精準醫療計劃中值得信賴的合作夥伴。

採用透明的三角驗證調查方法，結合一手訪談、技術評估和供應鏈分析，得出可操作的結論。

本分析所依據的研究整合了多方面的證據，以確保方法的嚴謹性和實際應用價值。研究人員對價值鏈上的各相關人員進行了初步的定性訪談，包括分子生物學實驗室主任、轉化研究人員、委外研發機構負責人。這些訪談有助於了解影響miRNA定序和檢測解決方案採用決策的營運限制、檢驗重點和買方偏好。

除了初步訪談外，技術評估還考察了實驗室規程、檢測性能文獻以及公開的監管指南，以評估方法學的優勢和常見失效模式。供應鏈圖譜追蹤了試劑和設備採購的關鍵節點，採購案例研究描述了各組織如何調整採購策略以應對政策和物流壓力。競爭格局分析考察了產品系列、服務產品和夥伴關係策略，以識別通用的差異化和價值獲取模式。

資料三角測量法整合了定性見解和技術證據，從而對該技術的發展軌跡和應用促進因素得出確切結論。檢驗標準盡可能強調可重複性、正交驗證路徑以及支援臨床應用的文件完整性。此方法著重於透明度和可追溯性，記錄分析決策的來源和理由，以便讀者評估其對自身專案和投資決策的影響。

最終整合著重於檢驗、協作和營運準備，以此作為將 miRNA 研究成果轉化為臨床影響的途徑。

總之，miRNA定序和檢測技術在發現科學和臨床應用的交叉領域中佔據關鍵地位。定序平台、檢測化學和生物資訊學的進步正在提高小RNA訊號的保真度和可解釋性，從而擴大其臨床和研究應用範圍。然而，要充分發揮miRNA生物標記的潛力，還需要關注檢測方法的驗證、跨平台一致性以及供應鏈和法規環境中的實際操作問題。

相關人員若能協調技術研發、監管推廣和客戶互動方面的投資，將更有利於把發現的訊號轉化為臨床可操作的檢測方法和伴隨診斷。同時，切實可行的供應鏈策略和對本地市場的深入了解，對於幫助企業應對政策變化和特定地區的營運限制至關重要。展望未來，設備供應商、套件製造商、服務供應商和臨床合作夥伴之間的協作將推動標準化工作流程和證據包的完善，從而支持更廣泛的臨床應用。

嚴格的檢驗、透明的分析和靈活的服務模式為臨床醫生和支付方的信任創造了條件。對於致力於精準醫療的機構而言，投資於可重複的miRNA工作流程以及連接髮現和臨床領域的夥伴關係，將在生物標記開發和患者照護方面帶來持久的益處。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 新興的單細胞微型RNA分析平台能夠進行詳細的細胞異質性分析。
  • 整合人工智慧驅動的生物資訊流程，用於快速解讀miRNA表達數據和發現生物標記
  • 拓展細胞外囊泡 miRNA 檢測在非侵入性癌症診斷和即時病患監測的應用
  • 開發一種多重數位PCR檢測方法，用於臨床檢體中多種微型RNA的絕對定量。
  • 自動化高通量 miRNA定序工作流程的部署減少了人工操作時間，提高了可重複性。
  • 採用標準化的樣品製備套件，以最大限度地減少多個研究實驗室間微型RNA NGS結果的偏差。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 miRNA定序與檢測市場（依產品類型分類）

  • 表達檢測試劑套件
    • 微陣列試劑套件
    • qRT-PCR試劑套件
    • 定序套件
  • 定序平台
  • 服務
    • 生物資訊服務
    • 定序服務

9. miRNA定序和檢測市場（按技術分類）

  • 微陣列
  • 次世代定序
  • Rt-Qpcr

第10章 miRNA定序和檢測市場（按應用領域分類）

  • 臨床診斷
  • 疾病監測
  • 藥物發現

第11章 miRNA定序和檢測市場（按最終用戶分類）

  • 學術機構
  • 合約研究組織
  • 醫院和診斷實驗室
  • 製藥和生物技術

12. miRNA定序與檢測市場（依工作流程分類）

  • 消耗品
    • 套件和試劑
    • 實驗室設備
  • 服務
    • 數據分析服務
    • 定序服務

第13章 miRNA定序和檢測市場（按樣本類型分類）

  • 血
  • 血清/血漿
  • 組織

第14章 miRNA定序與檢測市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 miRNA定序和檢測市場（按組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國 miRNA 定序與檢測市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Illumina, Inc.
    • Thermo Fisher Scientific Inc.
    • QIAGEN NV
    • Agilent Technologies, Inc.
    • F. Hoffmann-La Roche Ltd
    • Bio-Rad Laboratories, Inc.
    • Takara Bio Inc.
    • New England Biolabs, Inc.
    • NanoString Technologies, Inc.
    • PerkinElmer, Inc.
Product Code: MRR-0A609A26A984

The miRNA Sequencing & Assay Market is projected to grow by USD 1,127.65 million at a CAGR of 14.55% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 380.21 million
Estimated Year [2025] USD 435.69 million
Forecast Year [2032] USD 1,127.65 million
CAGR (%) 14.55%

A comprehensive introduction to contemporary miRNA sequencing and assay capabilities that frame scientific potential and translational hurdles for clinical adoption

MicroRNA sequencing and assay science has rapidly matured from a niche research capability into a core element of molecular profiling strategies across translational research and clinical development. Advances in sample processing, library preparation chemistry, and analytical pipelines have increased the reliability of small RNA detection, while parallel improvements in instrumentation have compressed turn-around times and reduced the barrier to routine implementation. As a result, stakeholders across academic institutions, contract research organizations, hospitals and diagnostic laboratories, and pharmaceutical and biotech companies now evaluate miRNA solutions not just as exploratory tools but as candidates for biomarker development, companion diagnostics, and targeted therapeutic discovery.

Despite this progress, the field contends with persistent technical challenges that shape adoption decisions. Low input abundance, sequence similarity among family members, and the presence of isomiRs require highly selective assay design and rigorous quality controls. Moreover, bioinformatics workflows that translate raw reads into actionable signatures remain a differentiator; reproducible alignment, normalization, and annotation strategies determine whether a candidate miRNA achieves translational utility. Regulatory and clinical validation pathways introduce additional complexity, underlining the importance of integrated assays that pair robust wet-lab protocols with validated computational pipelines.

Transitioning from exploratory science to clinical utility calls for coordinated investments in assay standardization, cross-laboratory reproducibility studies, and partnerships that bridge instrument vendors, kit manufacturers, and service providers. In this context, emphasis on interoperable workflows and vendor-agnostic data formats is rising, enabling researchers and clinicians to compare results across platforms and accelerate the translation of miRNA signals into diagnostic and therapeutic insights. Taken together, these dynamics position miRNA sequencing and assay capabilities as pivotal enablers of precision medicine initiatives when implemented with methodological rigor and strategic alignment to clinical goals.

Critical transformative shifts reshaping miRNA sequencing and assay workflows that enable scalable clinical translational pathways and integrated service models

The landscape of miRNA sequencing and assay development is undergoing several transformative shifts that redefine technical expectations and commercial strategies. Next generation sequencing platforms have extended sensitivity and multiplexing capacity, enabling simultaneous profiling of hundreds of small RNAs from reduced sample inputs, which in turn drives new use cases in longitudinal monitoring and minimally invasive sampling. Concurrently, improvements in assay chemistry and library preparation have reduced bias and increased uniformity across sequencing runs, making cross-study comparison increasingly feasible and fueling broader interest from clinical research programs.

At the same time, the convergence of RT-qPCR, microarray, and sequencing approaches has created a tiered diagnostics ecosystem in which high-throughput discovery via sequencing is complemented by targeted validation using qRT-PCR assays or microarray panels. This multi-modal pathway supports rigorous biomarker qualification: discovery, orthogonal validation, and then deployment in a regulated clinical testing environment. Alongside wet-lab evolution, bioinformatics and machine learning algorithms have matured to handle small-RNA specific challenges, including isomiR detection, sequence trimming artifacts, and cross-platform normalization, thereby enhancing confidence in derived signatures.

Operational shifts are also evident. Service providers are expanding offerings to include end-to-end solutions that combine sample logistics, sequencing execution, and interpretive analytics, while instrument and reagent manufacturers prioritize integrated workflows that improve ease of adoption for clinical labs. Policy and payer discourse is increasingly focused on evidentiary standards for molecular biomarkers, prompting closer collaboration among assay developers, clinical laboratories, and regulatory bodies to establish validation templates and performance benchmarks. Taken together, these shifts are moving miRNA assays from experimental workflows toward standardized components of precision medicine pipelines.

How evolving tariff dynamics have reshaped supply-chain strategy, procurement practices, and resiliency planning across miRNA sequencing and assay operations

Recent trade policy adjustments have introduced an additional layer of complexity into procurement planning, supply-chain design, and cost management for organizations that rely on imported instruments, consumables, and reagents. Tariff actions affecting imported laboratory equipment and reagents have increased the effective landed cost for many market participants, prompting procurement teams to reassess vendor relationships, contract terms, and inventory strategies. In response, some organizations have accelerated efforts to diversify suppliers and source critical inputs from geographically closer manufacturers to mitigate exposure to cross-border policy shifts.

These dynamics have material operational consequences. Research institutions and clinical laboratories are adapting purchasing cadences, increasing buffer stocks of essential reagents, and extending supplier qualification processes to include alternative domestic and regional partners. Manufacturers and distributors, for their part, are exploring localized assembly, alternative logistics routing, and restructured pricing models to preserve customer access while managing margin pressures. Service providers that operate international sequencing centers are likewise evaluating where to locate capacity and how to structure customer pricing to reflect added duty and compliance costs.

Over time, sustained tariff pressures often catalyze investment in regional manufacturing capabilities and in strategic partnerships that reduce dependency on a single supply base. At the same time, procurement professionals and R&D leaders must weigh the trade-offs between supply resilience and the technical performance of alternative components. Continuing to monitor policy developments and proactively engaging with suppliers to understand inventory pipelines, lead times, and contingency arrangements will remain essential to maintain operational continuity and protect timelines for miRNA assay development and clinical validation.

Comprehensive segmentation insights that align product types, technologies, applications, workflows, end users, and sample type considerations to inform strategic investment

Interpreting the market requires attention to multiple segmentation vectors that collectively define product design, adoption pathways, and user requirements. Based on product type, stakeholders must evaluate Expression Assay Kit options that include microarray kits, qRT-PCR kits, and sequencing kits alongside sequencing platforms and a range of services that span bioinformatics services and sequencing services. Each product class demands distinct validation standards and support models: microarray and qRT-PCR kits are often optimized for targeted panels and clinical throughput, whereas sequencing kits and platforms favor discovery breadth and multiplex capacity. Services that provide bioinformatics and sequencing execution bridge the gap between raw data generation and actionable interpretation.

Technology segmentation highlights the co-existence of microarray, next generation sequencing, and RT-qPCR approaches, each providing a different balance of throughput, sensitivity, and cost per sample. Microarray solutions remain valuable for standardized panels and comparative studies, RT-qPCR is the workhorse for targeted validation and clinical assay confirmation, and next generation sequencing delivers comprehensive discovery and isoform-level resolution that supports research and novel biomarker identification.

When viewed through the lens of application, clinical diagnostics, disease research, and drug discovery each place unique demands on assay performance, regulatory documentation, and longitudinal reproducibility. End users including academic institutions, contract research organizations, hospitals and diagnostic laboratories, and pharmaceutical and biotech companies require differentiated support: academic teams favor openness and flexible protocols for exploratory work, CROs emphasize throughput and standardized reporting, clinical labs prioritize validated kits and compliance documentation, and industry sponsors focus on integration with clinical trial workflows.

Workflow segmentation divides offerings into consumables and services, where consumables include kits and reagents as well as labware and services encompass data analysis services and sequencing services. Consumable quality and batch consistency strongly influence downstream data reliability, while services that deliver sophisticated analytics are increasingly critical to translate complex small-RNA profiles into clinically meaningful readouts. Sample type further nuances product selection and protocol design; assays optimized for blood, serum/plasma, or tissue must address distinct pre-analytical variables such as RNA yield, degradation profiles, and matrix effects. Taken together, these segmentation perspectives frame where investments in assay optimization, regulatory strategy, and customer support will deliver the greatest return in adoption and impact.

Actionable regional insights that map innovation hubs, regulatory expectations, and operational realities across the Americas, EMEA, and Asia-Pacific regions

Regional dynamics strongly influence where innovation, clinical translation, and commercial traction occur, and each geography presents distinct regulatory, reimbursement, and operational considerations that shape adoption timelines. In the Americas, a concentration of academic research centers, translational institutes, and clinical trial activity drives demand for both discovery-grade sequencing platforms and validated assays for clinical studies. Clinical laboratories in this region often balance stringent regulatory expectations with early adoption by leading hospital systems and specialist diagnostic labs, which accelerates the pathway from biomarker discovery to clinical evaluation.

Across Europe, Middle East & Africa, regulatory harmonization efforts and established reimbursement frameworks create a landscape where assay validation and clinical-grade documentation receive pronounced emphasis. Public research funding and collaborative networks in several European markets support multi-center validation studies that enhance cross-validation and reproducibility. In the Middle East and Africa, pockets of investment in advanced diagnostics and research infrastructure are emerging; however, logistical considerations and supply-chain resilience often inform procurement strategies and partnerships in these markets.

The Asia-Pacific region is notable for a mix of high-volume manufacturing capacity, growing clinical research capabilities, and rapidly expanding hospital systems that are investing in molecular diagnostics. Local manufacturing hubs support reagent and consumable supply, while a growing base of clinical sequencing centers and contract research organizations expands service availability. Regulatory frameworks across the region vary, creating heterogeneity in clinical adoption speed, yet collaborative initiatives and public-private partnerships frequently accelerate localized validation and commercialization. Understanding these regional contrasts helps organizations tailor partnerships, localization efforts, and go-to-market strategies to the operational realities and clinical priorities of each geography.

Key competitive insights into how integrated workflows, strategic partnerships, and validated service models create durable advantages in miRNA sequencing and assay markets

Competitive dynamics in the miRNA sequencing and assay ecosystem center on differentiation through integrated workflows, validation evidence, and service breadth. Instrument and reagent suppliers that offer end-to-end solutions, from optimized library kits to validated bioinformatics pipelines, tend to reduce implementation friction for clinical laboratories and translational research teams. Service providers that combine sequencing capacity with domain-specific analytics create compelling value propositions for sponsors seeking turnkey biomarker programs, while specialized bioinformatics firms add value by delivering reproducible small-RNA pipelines and scalable interpretation frameworks.

Strategic partnerships and collaborations are a prevalent route to capability expansion. Alliances between kit manufacturers and clinical laboratories, or between sequencing centers and pharmaceutical sponsors, enable co-development of assays and shared validation studies that accelerate clinical qualification. At the same time, competition for clinical and commercial customers emphasizes the need for robust customer support, training, and documentation that demonstrate assay performance and clinical utility. Intellectual property around assay chemistry and computational methods can create barriers to entry but also opportunities for licensing and white-label offerings.

Operational excellence differentiates market leaders. Firms that invest in quality management systems, regulatory affairs expertise, and transparent validation data tend to build greater trust with hospital laboratories and diagnostic networks. Additionally, companies that offer flexible commercial models, including subscription analytics, per-sample sequencing services, and bespoke panel development, appeal to a broader set of end users. Ultimately, sustained competitive advantage will accrue to organizations that combine rigorous technical validation with service models that align to clinical workflows and the reimbursement realities of diverse health systems.

Practical and prioritized recommendations for industry leaders to fast-track assay validation, supply resilience, and clinical integration for miRNA initiatives

Leaders seeking to maximize the impact of miRNA sequencing and assay investments should pursue a coordinated set of strategic actions that address technical robustness, supply-chain resilience, and downstream clinical integration. Prioritize rigorous assay validation and cross-platform concordance studies to demonstrate reproducibility and to facilitate adoption by clinical laboratories. Complement wet-lab validation with transparent, version-controlled bioinformatics pipelines and comprehensive documentation that support regulatory submissions and clinical accreditation processes.

Diversify sourcing strategies to reduce exposure to sudden tariff or logistics disruptions, while simultaneously cultivating regional manufacturing or distribution partnerships where feasible. Invest in supplier qualification processes, extended reagent inventory planning, and contractual terms that support continuity of supply. From a commercial perspective, design modular offerings that couple discovery sequencing with orthogonal validation options such as RT-qPCR panels or microarray confirmations, enabling customers to progress from research to clinical validation within a coherent framework.

Strengthen customer enablement through training programs, shared protocols, and on-site or virtual assay setup services that reduce implementation risk for laboratories. Engage early and proactively with clinical stakeholders, payers, and regulatory advisors to articulate evidence generation pathways and to de-risk reimbursement conversations. Finally, prioritize data governance, interoperability, and security to foster clinician trust and to support multi-center validation efforts. By aligning technical rigor with operational resilience and customer-centric service design, organizations can accelerate translational progress and position themselves as trusted partners in precision medicine initiatives.

A transparent, triangulated research methodology combining primary interviews, technical assessments, and supply-chain analysis to support actionable conclusions

The research underpinning this analysis combined multiple evidence streams to ensure methodological rigor and practical relevance. Primary qualitative interviews were conducted with stakeholders across the value chain, including molecular laboratory directors, translational researchers, procurement leads, and leaders of contract research organizations. These conversations informed an understanding of operational constraints, validation priorities, and buyer preferences that shape adoption decisions for miRNA sequencing and assay solutions.

Complementing primary interviews, technical assessments reviewed laboratory protocols, assay performance literature, and publicly available regulatory guidance to evaluate methodological strengths and common failure modes. Supply-chain mapping exercises traced key nodes for reagent and instrument availability, while procurement case studies illustrated how organizations adapt purchasing strategies in response to policy or logistics pressures. Competitive landscape analysis examined product portfolios, service offerings, and partnership strategies to identify common patterns of differentiation and value capture.

Data triangulation methods synthesized qualitative insights with technical evidence, enabling robust conclusions about technology trajectories and adoption levers. Wherever feasible, validation criteria emphasized reproducibility, orthogonal confirmation pathways, and the completeness of documentation that supports clinical use. The methodology focused on transparency and traceability, documenting sources and rationale for analytical judgments so that readers can assess implications for their own programs and investment decisions.

A conclusive synthesis emphasizing validation, collaboration, and operational readiness as the pathway to transform miRNA insights into clinical impact

In sum, miRNA sequencing and assay capabilities occupy a pivotal position at the intersection of discovery science and clinical translation. Advances in sequencing platforms, assay chemistries, and bioinformatics have collectively improved the fidelity and interpretability of small-RNA signals, expanding the range of viable clinical and research applications. Yet realizing the full potential of miRNA biomarkers requires disciplined attention to assay validation, cross-platform concordance, and the operational realities of supply chains and regulatory environments.

Stakeholders that align investments across technical development, regulatory engagement, and customer enablement will be best positioned to convert discovery-stage signals into clinically actionable tests and therapeutic companion diagnostics. At the same time, pragmatic supply-chain strategies and regional market understanding will prove critical as organizations navigate policy shifts and localized operational constraints. Moving forward, collaboration among instrument suppliers, kit manufacturers, service providers, and clinical partners will accelerate maturation of standardized workflows and evidence packages that support broader clinical adoption.

The path from characterization to clinical impact is iterative: rigorous validation, transparent analytics, and responsive service models create the conditions for trust among clinicians and payers. For organizations focused on precision medicine, investing in reproducible miRNA workflows and in partnerships that bridge discovery and clinical practice will yield durable benefits in biomarker development and patient care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emergence of single-cell microRNA profiling platforms enabling detailed cellular heterogeneity analysis
  • 5.2. Integration of AI-driven bioinformatics pipelines for rapid miRNA expression data interpretation and biomarker discovery
  • 5.3. Expansion of extracellular vesicle miRNA assay applications for non-invasive cancer diagnostics and real-time patient monitoring
  • 5.4. Development of multiplexed digital PCR assays for absolute quantification of diverse microRNAs in clinical specimens
  • 5.5. Rollout of automated high-throughput miRNA sequencing workflows reducing hands-on time and enhancing reproducibility
  • 5.6. Adoption of standardized library preparation kits to minimize biases in microRNA NGS results across multiple research laboratories

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. miRNA Sequencing & Assay Market, by Product Type

  • 8.1. Expression Assay Kit
    • 8.1.1. Microarray Kit
    • 8.1.2. Qrt-Pcr Kit
    • 8.1.3. Sequencing Kit
  • 8.2. Sequencing Platform
  • 8.3. Services
    • 8.3.1. Bioinformatics Services
    • 8.3.2. Sequencing Services

9. miRNA Sequencing & Assay Market, by Technology

  • 9.1. Microarray
  • 9.2. Next Generation Sequencing
  • 9.3. Rt-Qpcr

10. miRNA Sequencing & Assay Market, by Application

  • 10.1. Clinical Diagnostics
  • 10.2. Disease Research
  • 10.3. Drug Discovery

11. miRNA Sequencing & Assay Market, by End User

  • 11.1. Academic Institutions
  • 11.2. Contract Research Organizations
  • 11.3. Hospitals & Diagnostic Laboratories
  • 11.4. Pharmaceutical & Biotech

12. miRNA Sequencing & Assay Market, by Workflow

  • 12.1. Consumables
    • 12.1.1. Kits & Reagents
    • 12.1.2. Labware
  • 12.2. Services
    • 12.2.1. Data Analysis Services
    • 12.2.2. Sequencing Services

13. miRNA Sequencing & Assay Market, by Sample Type

  • 13.1. Blood
  • 13.2. Serum/Plasma
  • 13.3. Tissue

14. miRNA Sequencing & Assay Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. miRNA Sequencing & Assay Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. miRNA Sequencing & Assay Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Illumina, Inc.
    • 17.3.2. Thermo Fisher Scientific Inc.
    • 17.3.3. QIAGEN N.V.
    • 17.3.4. Agilent Technologies, Inc.
    • 17.3.5. F. Hoffmann-La Roche Ltd
    • 17.3.6. Bio-Rad Laboratories, Inc.
    • 17.3.7. Takara Bio Inc.
    • 17.3.8. New England Biolabs, Inc.
    • 17.3.9. NanoString Technologies, Inc.
    • 17.3.10. PerkinElmer, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY WORKFLOW, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY WORKFLOW, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE MIRNA SEQUENCING & ASSAY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST MIRNA SEQUENCING & ASSAY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC MIRNA SEQUENCING & ASSAY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN MIRNA SEQUENCING & ASSAY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC MIRNA SEQUENCING & ASSAY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION MIRNA SEQUENCING & ASSAY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 MIRNA SEQUENCING & ASSAY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO MIRNA SEQUENCING & ASSAY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. MIRNA SEQUENCING & ASSAY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. MIRNA SEQUENCING & ASSAY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. MIRNA SEQUENCING & ASSAY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY MICROARRAY KIT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY MICROARRAY KIT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY MICROARRAY KIT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY MICROARRAY KIT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY MICROARRAY KIT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY MICROARRAY KIT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY QRT-PCR KIT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY QRT-PCR KIT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY QRT-PCR KIT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY QRT-PCR KIT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY QRT-PCR KIT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY QRT-PCR KIT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING KIT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING KIT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING KIT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING KIT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING KIT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING KIT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING PLATFORM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING PLATFORM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING PLATFORM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING PLATFORM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING PLATFORM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING PLATFORM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY BIOINFORMATICS SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY BIOINFORMATICS SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY BIOINFORMATICS SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY BIOINFORMATICS SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY BIOINFORMATICS SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY BIOINFORMATICS SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY MICROARRAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY MICROARRAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY RT-QPCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY RT-QPCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY RT-QPCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY RT-QPCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY RT-QPCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY RT-QPCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY DISEASE RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY DISEASE RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY DISEASE RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY DISEASE RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY DISEASE RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY DISEASE RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PHARMACEUTICAL & BIOTECH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PHARMACEUTICAL & BIOTECH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PHARMACEUTICAL & BIOTECH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PHARMACEUTICAL & BIOTECH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PHARMACEUTICAL & BIOTECH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PHARMACEUTICAL & BIOTECH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY WORKFLOW, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY WORKFLOW, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY KITS & REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY KITS & REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY KITS & REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY KITS & REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY KITS & REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY KITS & REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY LABWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY LABWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY LABWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY LABWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY LABWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY LABWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY DATA ANALYSIS SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY DATA ANALYSIS SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY DATA ANALYSIS SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY DATA ANALYSIS SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY DATA ANALYSIS SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY DATA ANALYSIS SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY BLOOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY BLOOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY BLOOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERUM/PLASMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERUM/PLASMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERUM/PLASMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERUM/PLASMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERUM/PLASMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERUM/PLASMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TISSUE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TISSUE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TISSUE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TISSUE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TISSUE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TISSUE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY WORKFLOW, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY WORKFLOW, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY WORKFLOW, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY WORKFLOW, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY WORKFLOW, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY WORKFLOW, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY WORKFLOW, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY WORKFLOW, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE MIRNA SEQUENCING & ASSAY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE MIRNA SEQUENCING & ASSAY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE MIRNA SEQUENCING & ASSAY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE MIRNA SEQUENCING & ASSAY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE MIRNA SEQUENCING & ASSAY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE MIRNA SEQUENCING & ASSAY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE MIRNA SEQUENCING & ASSAY MARKET SIZE, BY WORKFLOW, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE MIRNA SEQUENCING & ASSAY MARKET SIZE, BY WORKFLOW, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. MIDDLE EAST MIRNA SEQUENCING & ASSAY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. MIDDLE EAST MIRNA SEQUENCING & ASSAY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. MIDDLE EAST MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. MIDDLE EAST MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 303. MIDDLE EAST MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, 2018-2024 (USD MILLION)
  • TABLE 304. MIDDLE EAST MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, 2025-2032 (USD MILLION)
  • TABLE 305. MIDDLE EAST MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 306. MIDDLE EAST MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 307. MIDDLE EAST MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 308. MIDDLE EAST MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TECHNOL